ES2107051T3 - Formulaciones de proteinas de liberacion sostenida. - Google Patents

Formulaciones de proteinas de liberacion sostenida.

Info

Publication number
ES2107051T3
ES2107051T3 ES93920157T ES93920157T ES2107051T3 ES 2107051 T3 ES2107051 T3 ES 2107051T3 ES 93920157 T ES93920157 T ES 93920157T ES 93920157 T ES93920157 T ES 93920157T ES 2107051 T3 ES2107051 T3 ES 2107051T3
Authority
ES
Spain
Prior art keywords
sustained release
protein formulations
release protein
sustained
novel compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920157T
Other languages
English (en)
Inventor
Michael J Hageman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2107051T3 publication Critical patent/ES2107051T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL INVENTO PROPORCIONA NUEVAS COMPOSICIONES UTILES PARA LA LIBERACION SOSTENIDA DE PROTEINAS BIOACTIVAS. MAS ESPECIFICAMENTE, EL PRESENTE INVENTO SE REFIERE A NUEVAS SUSPENSIONES DE UNA PROTEINA O PEPTIDO, MAS PARTICULARMENTE SOMATOTROPINAS Y FACTORES LIBERADORES DE LA HORMONA DEL CRECIMIENTO, EN GLICOL DE POLIETILENO O TRIACETINA. TAMBIEN SE FACILITAN METODOS PARA EMPLEAR ESTAS NUEVAS COMPOSICIONES COMO VEHICULOS DE LIBERACION SOSTENIDA O PROLONGADA DE PROTEINA BIOACTIVA O PEPTIDO.
ES93920157T 1992-09-21 1993-08-23 Formulaciones de proteinas de liberacion sostenida. Expired - Lifetime ES2107051T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94787292A 1992-09-21 1992-09-21
US96336592A 1992-10-20 1992-10-20

Publications (1)

Publication Number Publication Date
ES2107051T3 true ES2107051T3 (es) 1997-11-16

Family

ID=27130263

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920157T Expired - Lifetime ES2107051T3 (es) 1992-09-21 1993-08-23 Formulaciones de proteinas de liberacion sostenida.

Country Status (12)

Country Link
US (1) US6011011A (es)
EP (1) EP0661989B1 (es)
JP (2) JP3756512B2 (es)
AT (1) ATE156361T1 (es)
AU (1) AU5018693A (es)
DE (1) DE69312947T2 (es)
DK (1) DK0661989T3 (es)
ES (1) ES2107051T3 (es)
GR (1) GR3024632T3 (es)
MX (1) MX9305729A (es)
TW (1) TW224055B (es)
WO (1) WO1994006452A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0873134T3 (da) * 1996-01-11 2003-08-11 Upjohn Co Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
KR100594519B1 (ko) * 1996-07-03 2007-03-02 앨자 코포레이션 비수성양성자성펩티드제제
KR100593221B1 (ko) * 1996-07-03 2007-03-02 알자 코포레이션 비수성극성비양성자성펩타이드제제
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
CA2259403A1 (en) * 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
IN184589B (es) 1996-10-16 2000-09-09 Alza Corp
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
AU2002211629A1 (en) * 2000-10-10 2002-04-22 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
KR100838219B1 (ko) * 2001-07-13 2008-06-13 동아제약주식회사 인간성장호르몬의 지속적인 방출이 가능한 생분해성약학적 조성물 및 미립구 제형
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7074425B2 (en) * 2002-09-26 2006-07-11 Bonewax, Llc Hemostatic compositions and methods
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1663296A4 (en) * 2003-09-25 2009-11-25 Cangene Corp LIQUID FORMULATION OF HUMAN GROWTH HORMONE CONTAINING POLYETHYLENE GLYCOL
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
WO2006081279A2 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
MY139088A (en) 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
CA2610159C (en) * 2005-06-10 2015-03-31 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2209371B1 (en) * 2007-10-19 2017-01-04 SARcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
EP2214643B1 (en) * 2007-11-02 2014-04-02 Acrux DDS Pty Ltd Transdermal delivery system for hormones and steroids
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
DE102009056745A1 (de) * 2009-12-04 2011-06-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung von Peptiden
JP2013515080A (ja) * 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
AU2010341518B2 (en) * 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
UY34913A (es) * 2012-07-17 2013-12-31 Bayer New Zealand Ltd Formaciones inyectables de antibiótico y sus métodos de aplicación
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
KR20180063311A (ko) * 2015-10-16 2018-06-11 리제너론 파마슈티칼스 인코포레이티드 안정한 단백질 조성물
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1185340A (en) * 1967-12-19 1970-03-25 Gen Foods Corp Water Dispersable Hydrophilic Colloid Composition.
US4041155A (en) * 1974-10-29 1977-08-09 American Home Products Corporation Long acting somatostatin composition
US3966962A (en) * 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
US4301175A (en) * 1980-12-29 1981-11-17 The Upjohn Company E-Type prostaglandin compositions
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
DE3484584D1 (de) * 1983-10-14 1991-06-20 Sumitomo Pharma Injektionen mit verzoegerter abgabe.
JPS60224638A (ja) * 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
FR2606597B1 (fr) * 1986-11-17 1989-01-27 Rhone Poulenc Sante Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5004728A (en) * 1988-03-11 1991-04-02 The Trustees Of The University Of Pennsylvania Methods of increasing milk yields in ruminants
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
DE4015794A1 (de) * 1989-05-16 1990-11-29 Puetter Medice Chem Pharm Pharmazeutische zubereitung
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
ATE164080T1 (de) * 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments

Also Published As

Publication number Publication date
EP0661989A1 (en) 1995-07-12
ATE156361T1 (de) 1997-08-15
JP2004285079A (ja) 2004-10-14
DE69312947D1 (de) 1997-09-11
US6011011A (en) 2000-01-04
WO1994006452A1 (en) 1994-03-31
GR3024632T3 (en) 1997-12-31
MX9305729A (es) 1994-03-31
JP3756512B2 (ja) 2006-03-15
EP0661989B1 (en) 1997-08-06
AU5018693A (en) 1994-04-12
JPH08501305A (ja) 1996-02-13
DK0661989T3 (da) 1998-03-02
TW224055B (es) 1994-05-21
DE69312947T2 (de) 1998-01-08

Similar Documents

Publication Publication Date Title
ES2107051T3 (es) Formulaciones de proteinas de liberacion sostenida.
HK1021824A1 (en) Compositions and methods for treating infections using analogues of indolicidin
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
EP1686172A3 (en) Myocardial grafts and cellular compositions useful for same
ATE244015T1 (de) Formulierungen fuer faktor ix
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
EP1200124A4 (en) IMMUNOGLOBIN FUSION PROTEINS
NZ227787A (en) Peptides and compositions having growth hormone regulatory effects
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
AU575843B2 (en) Growth hormone releasing peptides
EA200000685A1 (ru) Комплекс ifnar2/ifn
WO2002044197A3 (en) Cytokine receptor binding peptides
WO2002058589A3 (en) Agents and methods for promoting bone growth
IL95863A0 (en) Anticoagulant peptides and compositions containing them
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
TR199901054T2 (xx) Bi�imsel olarak k�s�tlanm�� LH-RH analoglar�, bunlar�n kullan�mlar� ve bunlar� i�eren farmas�tik terkipler.
EP0723016A3 (en) Leukocyte activation factor
SE9604439D0 (sv) New receptor
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 661989

Country of ref document: ES